RKLY - RKLY STOCK NEWS

Rockley Photonics (NYSE: RKLY) will report its first quarter 2022 financial results on April 27, 2022 after market close. A conference call to discuss the results and future business outlook is scheduled for 5:00 p.m. ET that same day. Investors can access the call by dialing 877-407-0784 in the U.S. or +1 201-689-8560 internationally. A live webcast will also be available on Rockley's investor relations page. The company is recognized for its advancements in photonics technology across various industries.

Rockley Photonics (NYSE: RKLY) has partnered with Medtronic to develop the Bioptx™ biomarker sensing platform. This collaboration aims to create regulated wearable devices for continuous health monitoring. The technology will enable real-time, non-invasive tracking of multiple health markers, including body temperature, blood pressure, and glucose levels. The partnership emphasizes proactive healthcare and personalized treatment. Rockley anticipates shipping its first wearable devices to Medtronic in the second half of 2022, marking a significant step forward in medical technology innovation.

Rockley Photonics (NYSE: RKLY) reported its 2021 financial results, showing a 63% revenue decline to $8.2 million from $22.3 million in 2020. Despite this, gross profit improved to $2.7 million compared to a loss in Q3 2021. The company introduced its Bioptx™ biomarker sensing platform to the professional healthcare market and expanded partnerships in consumer wearables, targeting significant growth in 2022. Net loss narrowed significantly to $14.7 million in Q4 compared to $58 million the previous quarter. The 2022 revenue outlook is projected between $20 - $30 million.

Rockley Photonics (NYSE: RKLY) has appointed Nicolaus Henke as an independent director on its board, effective February 16, 2022. Henke brings over 35 years of experience, including 30 years at McKinsey & Company, where he led their healthcare practice globally. His expertise in AI and machine learning is expected to enhance Rockley's strategic direction. This appointment expands the board to eight members, aiming to strengthen governance and drive growth in photonics-based health monitoring technologies.

Rockley Photonics (NYSE: RKLY) will announce its fourth quarter and full year 2021 financial results on March 8, 2022, after market hours, followed by a conference call at 5:00 p.m. Eastern Time. The call will discuss financial results and future guidance. Investors can access the call via a dedicated phone line or a live webcast available on Rockley’s investor relations page. A replay will be available until March 22, 2022. Rockley focuses on photonics-based health monitoring and communications solutions, targeting diverse high-volume markets.

Rockley Photonics Holdings Limited (NYSE: RKLY) has announced senior leadership promotions to enhance its biomarker sensing solutions for health and wellness. Key promotions include Hooman Abediasl as EVP of Product Engineering, Sanjiv Kapoor as EVP of Operations, and Roozbeh Parsa as EVP of Commercial. Rockley aims to leverage these executives' extensive expertise to accelerate the development of its health monitoring technology.

CEO Andrew Rickman expressed confidence in the management team's capabilities, emphasizing their potential to drive innovation and capitalize on growth opportunities.

Rockley Photonics (NYSE: RKLY) has launched its Bioptx™ platform, an advanced biomarker sensing solution aimed at the medical and healthcare markets. The platform, which includes a non-invasive biosensing wristband, cloud analytics, and AI, enables real-time monitoring of health metrics such as body temperature and glucose levels. Notably, engineering samples were shipped two years ahead of schedule to meet demand, with commercial products expected in late 2022. The initiative is projected to expand Rockley’s market opportunity by $15 billion, enhancing its capabilities in remote patient monitoring and chronic condition management.

Rockley Photonics (NYSE: RKLY) has joined the Center to Stream Healthcare in Place (C2SHIP), a consortium funded by the U.S. National Science Foundation. This partnership aims to enhance in-home healthcare solutions using Rockley's multi-biomarker wearable sensing technologies. The collaboration includes prominent academic institutions such as the University of Arizona and Baylor College of Medicine. Rockley anticipates its technology will meet the growing demand for non-invasive monitoring outside clinical settings, thereby improving personalized healthcare.

Rockley Photonics has completed a pilot study demonstrating the ability of its wrist-worn device to measure blood pressure non-invasively. This technology, set to enhance cardiovascular health monitoring, showed stronger correlations with traditional cuff measurements compared to typical PPG devices. The study involved 40 subjects and yielded over 480 readings, paving the way for expanded biomarker detection capabilities. Rockley continues to engage with 17 global manufacturers, establishing a foothold in consumer electronics and medical devices.